Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
Roche is stepping up the defence of its eye franchise, but the real test will come with pivotal readouts for its new contender versus Regeneron’s Eylea.
Krystal Biotech shares have surged 53% so far this week on gene therapy data in two patients, but rivals are waiting in the wings.
Promising mid-stage data with Merck KGaA’s evobrutinib in multiple sclerosis could help the German group carve out a niche for its BTK inhibitor – unless bigger players…
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Companies that want to play in rare diseases need to shop for gene therapies, but price tags are looking rich.
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.